Novartis Ag (NVS) Cash & Current Investments (2009 - 2026)

Novartis Ag has disclosed Cash & Current Investments across 18 years of filings, most recently posting $7.7 billion for Q2 2026.

• In Q2 2026, Cash & Current Investments rose 9.86% year-over-year to $7.7 billion; the TTM figure through Jun 2026 stood at $7.7 billion (up 9.86% YoY), while the FY2025 annual figure was $11.6 billion, down 13.87% from the prior year.
• Cash & Current Investments came in at $7.7 billion for Q2 2026 at Novartis Ag, up from $7.0 billion in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $19.8 billion in Q2 2022 to a low of $7.0 billion in Q1 2026.
• Average Cash & Current Investments over 5 years is $12.4 billion, with a median of $11.8 billion recorded in 2023.
• Year-over-year, Cash & Current Investments surged 361.47% in 2022 and plunged 43.45% in 2023.
• Over 5 years, Cash & Current Investments stood at $18.9 billion in 2022, then retreated by 23.78% to $14.4 billion in 2023, then retreated by 6.73% to $13.5 billion in 2024, then declined by 13.87% to $11.6 billion in 2025, then plunged by 33.65% to $7.7 billion in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $7.7 billion in Q2 2026, $7.0 billion in Q1 2026, and $11.6 billion in Q4 2025.